Alps Group Inc.
(NASDAQ:ALPS) shares jumped 15.37% to $0.75 in after-hours trading on Tuesday after the Malaysia-headquartered biotech announced a research collaboration targeting patient-derived organoid technology for personalized cancer care.
Alps Group announced the agreement before the market opened on Tuesday.
The deal is with Dr.
Kong Wai Mun, Executive Director of Axiocell Biotech, positioning ALPS to build Malaysia's first clinically validated PDO platform, growing 3D "mini-tumors" from a patient's own cancer tissue to predict treatment response before therapy begins.






